These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 21720778)

  • 1. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
    Kikuchi M; Yamane T; Shinohara S; Fujiwara K; Hori SY; Tona Y; Yamazaki H; Naito Y; Senda M
    Ann Nucl Med; 2011 Nov; 25(9):625-33. PubMed ID: 21720778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
    Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
    J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice.
    Schütze C; Bergmann R; Brüchner K; Mosch B; Yaromina A; Zips D; Hessel F; Krause M; Thames H; Kotzerke J; Steinbach J; Baumann M; Beuthien-Baumann B
    Radiother Oncol; 2014 Apr; 111(1):81-7. PubMed ID: 24636842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
    Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study.
    Chang JH; Wada M; Anderson NJ; Lim Joon D; Lee ST; Gong SJ; Gunawardana DH; Sachinidis J; O'Keefe G; Gan HK; Khoo V; Scott AM
    Acta Oncol; 2013 Nov; 52(8):1723-9. PubMed ID: 23317145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer.
    Eschmann SM; Paulsen F; Bedeshem C; Machulla HJ; Hehr T; Bamberg M; Bares R
    Radiother Oncol; 2007 Jun; 83(3):406-10. PubMed ID: 17543402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO.
    Chen L; Zhang Z; Kolb HC; Walsh JC; Zhang J; Guan Y
    Nucl Med Commun; 2012 Oct; 33(10):1096-102. PubMed ID: 22836736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.
    Zschaeck S; Haase R; Abolmaali N; Perrin R; Stützer K; Appold S; Steinbach J; Kotzerke J; Zips D; Richter C; Gudziol V; Krause M; Zöphel K; Baumann M
    Acta Oncol; 2015; 54(9):1355-63. PubMed ID: 26398663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial.
    Mortensen LS; Johansen J; Kallehauge J; Primdahl H; Busk M; Lassen P; Alsner J; Sørensen BS; Toustrup K; Jakobsen S; Petersen J; Petersen H; Theil J; Nordsmark M; Overgaard J
    Radiother Oncol; 2012 Oct; 105(1):14-20. PubMed ID: 23083497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer.
    Rajendran JG; Schwartz DL; O'Sullivan J; Peterson LM; Ng P; Scharnhorst J; Grierson JR; Krohn KA
    Clin Cancer Res; 2006 Sep; 12(18):5435-41. PubMed ID: 17000677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
    Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases.
    Jansen JF; Schöder H; Lee NY; Wang Y; Pfister DG; Fury MG; Stambuk HE; Humm JL; Koutcher JA; Shukla-Dave A
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1403-10. PubMed ID: 19906496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential of [18F]-fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas.
    Henriques de Figueiredo B; Merlin T; de Clermont-Gallerande H; Hatt M; Vimont D; Fernandez P; Lamare F
    Strahlenther Onkol; 2013 Dec; 189(12):1015-9. PubMed ID: 24173497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
    Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
    Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
    Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
    Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxic volume evaluated by
    Sato J; Kitagawa Y; Watanabe S; Asaka T; Ohga N; Hirata K; Shiga T; Satoh A; Tamaki N
    Int J Oral Maxillofac Surg; 2018 May; 47(5):553-560. PubMed ID: 29030021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.
    Eschmann SM; Paulsen F; Reimold M; Dittmann H; Welz S; Reischl G; Machulla HJ; Bares R
    J Nucl Med; 2005 Feb; 46(2):253-60. PubMed ID: 15695784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma.
    Sato J; Kitagawa Y; Yamazaki Y; Hata H; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
    J Nucl Med; 2013 Jul; 54(7):1060-5. PubMed ID: 23699668
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Sato J; Kitagawa Y; Watanabe S; Asaka T; Ohga N; Hirata K; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2017 Sep; 124(3):261-270. PubMed ID: 28734696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: potential consequences for dose painting.
    Mammar H; Kerrou K; Nataf V; Pontvert D; Clemenceau S; Lot G; George B; Polivka M; Mokhtari K; Ferrand R; Feuvret L; Habrand JL; Pouysségur J; Mazure N; Talbot JN
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):681-7. PubMed ID: 22391104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.